IKS-03 by Iksuda Therapeutics for B-Cell Non-Hodgkin Lymphoma: Likelihood of...
IKS-03 is under clinical development by Iksuda Therapeutics and currently in Phase I for B-Cell Non-Hodgkin Lymphoma.
View ArticleIKS-03 by Iksuda Therapeutics for Diffuse Large B-Cell Lymphoma: Likelihood...
IKS-03 is under clinical development by Iksuda Therapeutics and currently in Phase I for Diffuse Large B-Cell Lymphoma.
View ArticleCapmatinib hydrochloride by Novartis for Metastatic Melanoma: Likelihood of...
Capmatinib hydrochloride is under clinical development by Novartis and currently in Phase II for Metastatic Melanoma.
View ArticleCapmatinib hydrochloride by Novartis for Metastatic Melanoma: Likelihood of...
Capmatinib hydrochloride is under clinical development by Novartis and currently in Phase II for Metastatic Melanoma.
View ArticleLinvoseltamab by Regeneron Pharmaceuticals for Multiple Myeloma (Kahler...
Linvoseltamab is under clinical development by Regeneron Pharmaceuticals and currently in Phase I for Multiple Myeloma (Kahler Disease).
View ArticlePidnarulex by Senhwa Biosciences for Breast Cancer: Likelihood of Approval
Pidnarulex is under clinical development by Senhwa Biosciences and currently in Phase I for Breast Cancer.
View ArticleMelpida by Elpida Therapeutics for Paraplegia: Likelihood of Approval
Melpida is under clinical development by Elpida Therapeutics and currently in Phase II for Paraplegia.
View ArticleNKX-019 by Nkarta for Refractory Chronic Lymphocytic Leukemia (CLL):...
NKX-019is under clinical development by Nkarta and currently in Phase I for Refractory Chronic Lymphocytic Leukemia (CLL).
View ArticleMirai Intex Honoured by ATMOsphere for Use of Natural Refrigerants
We are pleased to share some great news with you: our company, MIRAI INTEX, has been confirmed as a leader in innovation and sustainability in the refrigeration industry. We are proud to announce that...
View ArticleNew Research: 72% of Consumers Fear Health Information Misuse
Cassie, the consent management platform serving Fortune 500 companies globally, unveiled a new research report about consumer’s level of uncertainty with consent and data management within the US...
View ArticleGerresheimer at Pharmapack 2024: Innovative Solutions and Expert Presentations
Gerresheimer, an innovative system and solution provider and a global partner for the pharma, biotech and cosmetic industry, will present its comprehensive portfolio of containment solutions, drug...
View ArticlePharmaceutical Technology Excellence Awards 2023: dispenSense
dispenSense, part of Navi Group, is a Category Award Winner in three areas in the 2023 Pharmaceutical Technology Excellence Awards
View ArticleMirai Expands Its LNG Product Line for Gas Liquefaction
Amid the ongoing energy crisis, MIRAI INTEX is at the forefront of innovation, introducing three solutions designed to revolutionise the biogas liquefaction process: MIRAI Cold 50 LNG, MIRAI Cold 90...
View ArticleEli Lilly and Innovent’s obesity drug mazdutide achieves positive Phase III...
Innovent has reported positive Phase III results for mazdutide, Eli Lilly’s next-generation obesity asset that Innovent is developing as part of a 2019 deal with the company where it secured the rights...
View ArticleQ&A: Exploring the challenges behind oncology trials
Pauline Frank reflects on her talk at the 2023 CTO Europe conference and highlights some of the key issues in running oncology trials.
View ArticleMirai Cold LNG for Gas Liquefaction
MIRAI Cold LNG is an advanced solution precisely engineered for the precooling and liquefaction of biomethane. At the core of this system lies its innovative oil-free turbo compressor/expander. This...
View ArticleFive key factors to consider when selecting a granulation system for tablet...
Michael Schupp from Gerteis discusses what you should be looking for when choosing your granulation method.
View ArticleObesity disease management needs to be revolutionised
Obesity has only recently been recognised as a disease as opposed to a behavioural/lifestyle issue.
View Article
